Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03333824 · ClinicalTrials.gov registry record · Phase 1
Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT03333824 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 33 participants.
The verdict
NCT03333824, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether AZD1775 has any effect on the pharmacokinetics (PK) of three compounds (caffeine, omeprazole, and midazolam) that are probes for common drug-metabolizing enzymes (caffeine-CYP1A2, omeprazole-CYP2C19, midazolam-CYP3A). The study also seeks to determine the effect of AZD1775 on the QTc interval, which is a common measure of cardiac (heart) function.
Interventions
- DRUG Wee-1 kinase inhibitor AZD1775
- DRUG CYP1A2 (caffeine)
- DRUG CYP2C19 (omeprazole)
- DRUG CYP3A (midazolam)
- DRUG Kytril (granisetron)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2019-01-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03333824
The ClinicalTrials.gov registry entry for NCT03333824 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Wee-1 kinase inhibitor AZD1775 is the first listed.
NCT03333824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03333824 about?
NCT03333824 is a clinical study titled "Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer". The purpose of this study is to determine whether AZD1775 has any effect on the pharmacokinetics (PK) of three compounds (caffeine, omeprazole, and midazolam) that are probes for common drug-metabolizing enzymes (caffeine-CYP1A2, omeprazole-CYP2C19, midazolam-CYP3A). The study also seeks to determin...
What is the current status of trial NCT03333824?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2017-12-01. Estimated completion is 2019-01-22.
What interventions are being tested in trial NCT03333824?
The interventions under investigation include: Wee-1 kinase inhibitor AZD1775 (DRUG), CYP1A2 (caffeine) (DRUG), CYP2C19 (omeprazole) (DRUG), CYP3A (midazolam) (DRUG), Kytril (granisetron) (DRUG).
Who is sponsoring clinical trial NCT03333824?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.